Moody National Bank Trust Division Has $1.53 Million Stock Position in Gilead Sciences, Inc. $GILD

Moody National Bank Trust Division lowered its position in Gilead Sciences, Inc. (NASDAQ:GILD) by 28.7% during the fourth quarter, Holdings Channel reports. The firm owned 12,499 shares of the biopharmaceutical company’s stock after selling 5,037 shares during the period. Moody National Bank Trust Division’s holdings in Gilead Sciences were worth $1,534,000 at the end of the most recent quarter.

A number of other hedge funds have also bought and sold shares of GILD. Corundum Trust Company INC bought a new stake in shares of Gilead Sciences during the 3rd quarter valued at about $26,000. Howard Hughes Medical Institute purchased a new stake in Gilead Sciences during the second quarter worth about $30,000. MTM Investment Management LLC raised its position in Gilead Sciences by 176.0% in the third quarter. MTM Investment Management LLC now owns 276 shares of the biopharmaceutical company’s stock worth $31,000 after acquiring an additional 176 shares during the period. Kilter Group LLC purchased a new position in Gilead Sciences in the second quarter valued at about $33,000. Finally, Millstone Evans Group LLC lifted its stake in Gilead Sciences by 58.7% in the third quarter. Millstone Evans Group LLC now owns 319 shares of the biopharmaceutical company’s stock valued at $35,000 after purchasing an additional 118 shares during the last quarter. Institutional investors own 83.67% of the company’s stock.

Gilead Sciences Trading Up 0.6%

GILD stock opened at $138.11 on Wednesday. The company has a market capitalization of $171.42 billion, a PE ratio of 20.40, a price-to-earnings-growth ratio of 1.80 and a beta of 0.37. The company has a debt-to-equity ratio of 0.98, a quick ratio of 1.40 and a current ratio of 1.55. Gilead Sciences, Inc. has a one year low of $93.37 and a one year high of $157.29. The company’s 50 day moving average price is $143.31 and its two-hundred day moving average price is $128.32.

Gilead Sciences (NASDAQ:GILD) last released its earnings results on Tuesday, February 10th. The biopharmaceutical company reported $1.86 EPS for the quarter, beating the consensus estimate of $1.83 by $0.03. The company had revenue of $7.93 billion for the quarter, compared to analyst estimates of $7.68 billion. Gilead Sciences had a net margin of 28.90% and a return on equity of 49.46%. The firm’s quarterly revenue was up 4.7% compared to the same quarter last year. During the same quarter last year, the firm earned $1.90 EPS. Gilead Sciences has set its FY 2026 guidance at 8.450-8.850 EPS. As a group, analysts predict that Gilead Sciences, Inc. will post 7.95 earnings per share for the current fiscal year.

Gilead Sciences Increases Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Monday, March 30th. Stockholders of record on Friday, March 13th will be paid a dividend of $0.82 per share. This represents a $3.28 dividend on an annualized basis and a dividend yield of 2.4%. This is a boost from Gilead Sciences’s previous quarterly dividend of $0.79. The ex-dividend date of this dividend is Friday, March 13th. Gilead Sciences’s payout ratio is currently 48.45%.

Wall Street Analysts Forecast Growth

A number of equities analysts have weighed in on GILD shares. Bank of America set a $162.00 target price on Gilead Sciences and gave the stock a “buy” rating in a research note on Wednesday, February 11th. Needham & Company LLC reiterated a “buy” rating and set a $170.00 target price on shares of Gilead Sciences in a research report on Monday, February 23rd. Citigroup restated a “buy” rating on shares of Gilead Sciences in a research report on Friday, March 6th. Deutsche Bank Aktiengesellschaft lifted their price objective on shares of Gilead Sciences from $135.00 to $155.00 and gave the stock a “buy” rating in a report on Wednesday, February 11th. Finally, Mizuho increased their target price on Gilead Sciences from $140.00 to $170.00 and gave the company an “outperform” rating in a research note on Wednesday, February 18th. Twenty-four analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $157.62.

Gilead Sciences News Summary

Here are the key news stories impacting Gilead Sciences this week:

• Positive Sentiment: Gilead announced it will acquire Ouro Medicines for up to about $2.18 billion, adding OM336 (gamgertamig), a clinical-stage BCMAxCD3 T‑cell engager for autoimmune disease, which materially strengthens Gilead’s inflammation pipeline and diversifies revenue beyond HIV/oncology. Gilead Sciences to Acquire Ouro Medicines
• Positive Sentiment: Major outlets report the deal and highlight strategic rationale — buying a first‑in‑class T‑cell engager accelerates Gilead’s push into next‑gen immunology and could provide new growth avenues if OM336 advances clinically. Gilead to buy biotech firm Ouro Medicines
• Positive Sentiment: Analyst/press commentary (Barron’s, Zacks, Market commentators) frames the acquisition as a meaningful bet on “immune reset” and inflammation — narrative that can lift investor sentiment as Gilead stitches together an immunology franchise. Gilead to Buy Ouro Medicines for $2.2 Billion
• Neutral Sentiment: Gilead’s recent quarterly results showed a modest revenue beat and guidance for FY26 (8.45–8.85 EPS), which reduces short‑term execution concerns and pairs with the acquisition to shape the growth story. (Company filings/earnings release — background context)
• Neutral Sentiment: Multiple short‑interest reports for March show large increases in short interest but the published figures appear to be erroneous (zeros/NaN) and yield a 0.0 days‑to‑cover ratio; this data is not reliable for interpreting bearish positioning.
• Neutral Sentiment: A separate item on MaxCyte (MXCT) Q4 results is not related to Gilead and should not materially affect Gilead’s fundamentals. MaxCyte Q4 Results
• Negative Sentiment: M&A risks: the deal size (~$2B) increases near‑term cash/commitment and introduces execution and clinical risk — OM336 remains a clinical‑stage asset and eventual value depends on trial outcomes and integration/collaboration terms.

Insider Activity

In related news, CFO Andrew D. Dickinson sold 3,000 shares of the business’s stock in a transaction dated Monday, March 16th. The stock was sold at an average price of $144.23, for a total transaction of $432,690.00. Following the transaction, the chief financial officer owned 179,191 shares in the company, valued at $25,844,717.93. The trade was a 1.65% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, insider Johanna Mercier sold 28,000 shares of the stock in a transaction dated Tuesday, February 17th. The stock was sold at an average price of $154.44, for a total transaction of $4,324,320.00. Following the completion of the transaction, the insider directly owned 120,288 shares of the company’s stock, valued at approximately $18,577,278.72. The trade was a 18.88% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 309,280 shares of company stock worth $44,068,850 over the last ninety days. Company insiders own 0.27% of the company’s stock.

Gilead Sciences Company Profile

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.